ENDRA Life Sciences' TAEUS De Novo Submission Advances To Next Stage Of Review With FDA
Portfolio Pulse from Happy Mohamed
ENDRA Life Sciences Inc.'s De Novo request for the TAEUS liver system has advanced to the substantive review stage with the U.S. Food and Drug Administration (FDA). The TAEUS system is a proprietary device for non-invasive assessment of fatty liver tissue. The FDA aims to make a decision about a De Novo request in 150 review days. If granted, it will strengthen TAEUS' competitive position.
August 30, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ENDRA Life Sciences' TAEUS liver system has advanced to the next review stage with the FDA. A positive decision could strengthen TAEUS' competitive position and potentially boost NDRA's stock.
The advancement of the TAEUS liver system to the next review stage with the FDA is a positive development for ENDRA Life Sciences. If the FDA approves the De Novo request, it could strengthen TAEUS' competitive position, potentially leading to increased sales and a boost in NDRA's stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100